Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 12;3(2):e000164. doi: 10.1136/bmjno-2021-000164

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

At 14 months of nusinersen treatment, CMAP amplitude did not significantly correlate with age or disease duration, but was different between groups when stratified by ambulatory ability. CMAP amplitude was not associated with (A) age (r²=0.1681, p=0.1290, n=15) or (B) disease duration (r²=0.05957, p=0.4004, n=14). (C) When stratified by ambulatory ability, CMAP amplitude was significantly higher in ambulatory (5.3±2.1 mV, n=9) versus non-ambulatory (2.7±2.1 mV, n=6) participants following 14 months of nusinersen treatment (unpaired t-test, p=0.0326). CMAP amplitudes for analyses obtained in participants at 14 months of nusinersen. R² is the square of Pearson correlation coefficients. CMAP, compound muscle action potential.